Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Int J Cancer. 2012 Feb 1;130(3):575-83. doi: 10.1002/ijc.26063. Epub 2011 May 9.
Classical comparative genomic hybridization (CGH) has been used to identify recurrent genomic alterations in human HCC. As hepatocarcinogenesis is considered as a stepwise process, we applied oncogenetic tree modeling on all available classical CGH data to determine occurrence of genetic alterations over time. Nine losses (1p, 4q, 6q, 8p, 9p, 13q, 16p, 16q and 17p) and ten gains (1q, 5p, 6p, 7p, 7q, 8q, 17q, 20p, 20q and Xq) of genomic information were used to build the oncogenetic tree model. Whereas gains of 1q and 8q together with losses of 8p formed a cluster that represents early etiology-independent alterations, the associations of gains at 6q and 17q as well as losses of 6p and 9p were observed during tumor progression. HBV-induced HCCs had significantly more chromosomal aberrations compared to HBV-negative tumors. Losses of 1p, 4q and 13q were associated with HBV-induced HCCs, whereas virus-negative HCCs showed an association of gains at 5p, 7, 20q and Xq. Using five aberrations that were significantly associated with tumor dedifferentiation a robust progression model of stepwise human hepatocarcinogensis (gain 1q → gain 8q → loss 4q → loss 16q → loss 13q) was developed. In silico analysis revealed that protumorigenic candidate genes have been identified for each recurrently altered hotspot. Thus, oncogenic candidate genes that are coded on chromosome arms 1q and 8q are promising targets for the prevention of malignant transformation and the development of biomarkers for the early diagnosis of human HCC that may significantly improve the treatment options and thus prognosis of HCC patients.
经典比较基因组杂交(CGH)已被用于鉴定人类 HCC 中的复发性基因组改变。由于肝癌发生被认为是一个逐步的过程,我们对所有可用的经典 CGH 数据应用肿瘤发生树模型,以确定随时间发生的遗传改变。九个缺失(1p、4q、6q、8p、9p、13q、16p、16q 和 17p)和十个增益(1q、5p、6p、7p、7q、8q、17q、20p、20q 和 Xq)的基因组信息用于构建肿瘤发生树模型。虽然 1q 和 8q 的增益以及 8p 的缺失形成了一个代表早期病因无关改变的聚类,但在肿瘤进展过程中观察到了 6q 和 17q 的增益以及 6p 和 9p 的缺失的关联。HBV 诱导的 HCC 与 HBV 阴性肿瘤相比具有显著更多的染色体异常。1p、4q 和 13q 的缺失与 HBV 诱导的 HCC 相关,而病毒阴性 HCC 显示 5p、7、20q 和 Xq 的增益相关。使用与肿瘤去分化显著相关的五个畸变,开发了一个稳健的人类肝癌逐步发生的进展模型(增益 1q→增益 8q→缺失 4q→缺失 16q→缺失 13q)。计算机分析显示,每个反复改变的热点都鉴定出了促肿瘤候选基因。因此,编码在染色体臂 1q 和 8q 上的致癌候选基因是预防恶性转化和开发人类 HCC 早期诊断生物标志物的有希望的靶标,这可能显著改善 HCC 患者的治疗选择和预后。